Citadel Advisors
LUCD icon

Citadel Advisors’s Lucid Diagnostics LUCD Stock Holding History

Citadel Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-56,210
Closed -$61.3K – 13691
2025
Q4 		$61.3K Buy
+56,210
New +$62.8K ﹤0.01% 11936
2025
Q2 		– Sell
-121,430
Closed -$181K – 13988
2025
Q1 		$181K Buy
121,430
+1,543
+1% +$1.85K ﹤0.01% 10591
2024
Q4 		$98.2K Buy
+119,887
New +$106K ﹤0.01% 11511
2024
Q2 		– Sell
-29,301
Closed -$23.7K – 14947
2024
Q1 		$23.7K Sell
29,301
-338
-1% -$439 ﹤0.01% 12886
2023
Q4 		$41.8K Sell
29,639
-6,736
-19% -$8.88K ﹤0.01% 11973
2023
Q3 		$42.6K Sell
36,375
-26,136
-42% -$37.9K ﹤0.01% 11938
2023
Q2 		$86.9K Buy
+62,511
New +$94.2K ﹤0.01% 11137
2022
Q4 		– Sell
-35,333
Closed -$54K – 15217
2022
Q3 		$54K Buy
35,333
+4,506
+15% +$11.2K ﹤0.01% 11570
2022
Q2 		$70K Buy
30,827
+10,332
+50% +$23K ﹤0.01% 11708
2022
Q1 		$69K Buy
+20,495
New +$74.9K ﹤0.01% 12588

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Citadel Advisors's LUCD Position: Q1 2026 in Review

Citadel Advisors sold out of Lucid Diagnostics (LUCD) in Q1 2026, closing a stake of 56,210 shares — an estimated $61.3K sold.

Citadel Advisors first reported a position in LUCD in Q1 2022 and held it in 10 quarters. The position peaked at $181K in Q1 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Citadel Advisors reported no remaining Lucid Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 56,210 Lucid Diagnostics shares in Q1 2026, an estimated $61.3K.
  • Citadel Advisors first reported a position in Lucid Diagnostics in Q1 2022 and held it in 10 quarters.
  • Citadel Advisors's Lucid Diagnostics position peaked at $181K in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.